Babb JS - Search Results

1

Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.

Tighiouart M, Rogatko A, Babb JS. Tighiouart M, et al. Among authors: babb js. Stat Med. 2005 Jul 30;24(14):2183-96. doi: 10.1002/sim.2106. Stat Med. 2005. PMID: 15909291

2

New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.

Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G. Rogatko A, et al. Among authors: babb js. Clin Cancer Res. 2005 Aug 1;11(15):5342-6. doi: 10.1158/1078-0432.CCR-05-0458. Clin Cancer Res. 2005. PMID: 16061846

3

Patient specific dosing in a cancer phase I clinical trial.

Babb JS, Rogatko A. Babb JS, et al. Stat Med. 2001 Jul 30;20(14):2079-90. doi: 10.1002/sim.848. Stat Med. 2001. PMID: 11439422

4

Cancer phase I clinical trials: efficient dose escalation with overdose control.

Babb J, Rogatko A, Zacks S. Babb J, et al. Stat Med. 1998 May 30;17(10):1103-20. doi: 10.1002/(sici)1097-0258(19980530)17:10<1103::aid-sim793>3.0.co;2-9. Stat Med. 1998. PMID: 9618772

5

Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936.

Cheng JD, Babb JS, Langer C, Aamdal S, Robert F, Engelhardt LR, Fernberg O, Schiller J, Forsberg G, Alpaugh RK, Weiner LM, Rogatko A. Cheng JD, et al. Among authors: babb js. J Clin Oncol. 2004 Feb 15;22(4):602-9. doi: 10.1200/JCO.2004.12.034. J Clin Oncol. 2004. PMID: 14966084 Clinical Trial.

6

Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials.

Rogatko A, Babb JS, Wang H, Slifker MJ, Hudes GR. Rogatko A, et al. Among authors: babb js. Clin Cancer Res. 2004 Jul 15;10(14):4645-51. doi: 10.1158/1078-0432.CCR-03-0535. Clin Cancer Res. 2004. PMID: 15269136

7

Hardy-Weinberg equilibrium diagnostics.

Rogatko A, Slifker MJ, Babb JS. Rogatko A, et al. Among authors: babb js. Theor Popul Biol. 2002 Nov;62(3):251-7. doi: 10.1006/tpbi.2002.1613. Theor Popul Biol. 2002. PMID: 12408944

8

Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.

Haas N, Roth B, Garay C, Yeslow G, Entmacher M, Weinstein A, Rogatko A, Babb J, Minnitti C, Flinker D, Gillon T, Hudes G. Haas N, et al. Urology. 2001 Jul;58(1):59-64. doi: 10.1016/s0090-4295(01)01011-1. Urology. 2001. PMID: 11445480 Clinical Trial.

9

Constructing meiotic maps with known error probability.

Rogatko A, Babb J, Jordan H, Zacks S. Rogatko A, et al. Genet Epidemiol. 1999;16(3):274-89. doi: 10.1002/(SICI)1098-2272(1999)16:3<274::AID-GEPI4>3.0.CO;2-D. Genet Epidemiol. 1999. PMID: 10096690

10

Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinoma.

Cheng JD, Werness BA, Babb JS, Meropol NJ. Cheng JD, et al. Among authors: babb js. Clin Cancer Res. 1999 May;5(5):1057-62. Clin Cancer Res. 1999. PMID: 10353738

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

503 results

Search Page